Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To estimate the incidences of LPD, lymphoma and important infections over 2 years in subjects with RA who completed or discontinued a qualifying CP 690,550 clinical trial (randomized clinical trial with or without an open label extension).
Critère d'inclusion
- CP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA)